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Abstract
Background: Recently developed immunosuppressive drugs, especially TNF antagonists, may enhance the risk of
granulomatous infections, including leprosy. We aimed to evaluate the leprosy detection rate in patients under
immunosuppression due to rheumatological, dermatological and gastroenterological diseases.
Methods: We performed a systematic review of the literature by searching the PubMed, EMBASE, LILACS, Web of
Science and Scielo databases through 2018. No date or language restrictions were applied. We included all articles
that reported the occurrence of leprosy in patients under medication-induced immunosuppression.
Results: The search strategy resulted in 15,103 articles; finally, 20 articles were included, with 4 reporting
longitudinal designs. The detection rate of leprosy ranged from 0.13 to 116.18 per 100,000 patients/year in the USA
and Brazil, respectively. In the meta-analysis, the detection rate of cases of leprosy per 100,000 immunosuppressed
patients with rheumatic diseases was 84 (detection rate = 0.00084; 95% CI = 0.0000–0.00266; I2 = 0%, p = 0.55).
Conclusion: Our analysis showed that leprosy was relatively frequently detected in medication-induced
immunosuppressed patients suffering from rheumatological diseases, and further studies are needed. The lack of an
active search for leprosy in the included articles precluded more precise conclusions.
Trial registration: This review is registered in PROSPERO with the registry number CRD42018116275.
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Background
Biologics are the new paradigm in the treatment of auto-
immune diseases [1]. They represent the most important
pharmaceutical products sold in the US, as they are the
treatments most frequently prescribed for inflammatory
and autoimmune conditions [2]. They act on target mol-
ecules present in the pathophysiology of autoimmune
diseases, including cytokines and cell surface receptors,
constituting an important treatment strategy [3]. How-
ever, the target sites of immunobiological therapies also
play important roles in immune homeostasis and cell
cycle control. The blockage of these pathways tends to
alter immune function, with a consequent increased risk
of acute, latent, or chronic infections [3]. In addition,
abrupt discontinuation of these therapies may lead to a
paradoxical aggravation of an ongoing infection that is
triggered by the establishment of an inflammatory re-
constitution syndrome or worsening of the underlying
autoimmune disease [3].
The most common indications for these drugs are
dermatological, rheumatological and gastroenterological
conditions [4]. For instance, of the 15 indications for the
most commonly sold immunobiologic, adalimumab, 14
are classified as one of these conditions [5]. Biologics are
increasingly being used in areas where neglected tropical
diseases are common, such as India and Brazil [6–8].
Additionally, other tropical diseases, such as leprosy, still
occur in those countries [9–11]. The transmission of
leprosy is still a prevalent problem in many countries,
with 208,619 new cases diagnosed in 2018 [10].
Leprosy is a chronic infectious granulomatous disease
caused by Mycobacterium leprae that affects the skin
and peripheral nerves [12]. Clinically, it has two main
types: the tuberculoid form, represented by a strong
granulomatous reaction with few bacilli, and the lep-
romatous form, characterized by a high degree of bacilli
infiltration [13, 14]. Along the disease spectrum, there
are borderline clinical forms with immunological in-
stability and clinical characteristics of both types [15].
The natural history of leprosy is still not completely
understood, and only a minority of individuals who have
contact with the pathogen develop the disease [16, 17].
The proliferation of bacilli is determined by a combin-
ation of microbial, genetic and environmental factors.
Clinical disease implies the failure of human defences
against M. leprae [18]. Few cases have been reported in
patients using immunobiological drugs.
To reduce the risk of infections, new guidelines for the
use of immunobiological therapies have been developed,
with recommended patient assessments, including hepa-
titis B and C serology, syphilis and HIV tests, purified
protein derivative skin tests or interferon gamma release
assays, and chest radiography for the investigation of
tuberculosis, prior to the initiation of immunobiological
drug treatments. However, to date, there are no consist-
ent data or recommendations regarding tests for other
endemic diseases; new clinical pathways need to be
developed for the management of leprosy in this context
(Fig. 1).
To gain more insight into the magnitude of the prob-
lem, we aimed to evaluate the detection rate of leprosy
in patients under immunosuppression due to rheumato-
logical, dermatological and gastroenterological diseases.
We also aimed to create a clinical profile of affected
patients to describe the reported natural history of M.
leprae infection under these conditions and the aspects
of leprosy treatment.
Methods
This review is registered in PROSPERO under the registry
number CRD42018116275. On November 22nd, 2018, we
comprehensively searched the PubMed, EMBASE, Scopus,
Web of Science and Scielo databases. No date, language
or method restrictions were applied (S1 Table 1). We in-
cluded all articles that reported the occurrence of leprosy
in patients under immunosuppression for dermatological,
rheumatological, and gastroenterological diseases.
We excluded articles that reported immunosuppres-
sion due to other conditions, such as HIV infection,
chemotherapy and organ transplantation, because of the
different profiles of immunosuppression. We also ex-
cluded articles that reported leprosy cases that clearly
occurred before immunosuppression and cases in which
leprosy was wrongly treated as a rheumatic disease when
clinical manifestations of both diseases presented consid-
erable similarities. In addition, the analysis of follow-up
treatment for leprosy in patients undergoing immuno-
suppressive therapy should be considered in the future;
a more detailed analysis with a different search strategy
is needed.
Article selection and data extraction
After the search, all the retrieved articles were exported
to EPPI-Reviewer 4 Version 4.6.4.0 (EPPI Centre,
London, England), and duplicates were removed with
the aid of the automatic tool in the program and subse-
quently manually checked. Due to the high number of
references included, two groups of two independent
reviewers (CG (investigator) + JB (epidemiologist) and
DB (investigator) + EA (epidemiologist)) screened the
titles and abstracts. Disagreements were resolved by a
third reviewer (PK (investigator)).
Two independent reviewers screened the full texts and
extracted the data (CG +DB and CG +AC (investigator)).
A third reviewer resolved any disagreements in both steps
(PK). The references of selected articles were also
screened. The extracted data are presented in S2 Table 2.
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Quality assessment
Although there is considerable variability in the available
methods of outcome evaluation, we opted to use the
Johanna Briggs Checklist for Analytical Cross-Sectional
Studies. This tool is capable of generating a homoge-
neous evaluation for studies in which the extraction of
period prevalence data (expressed as the leprosy detec-
tion rate) is possible even when screening studies that
do not necessarily include groups with different expo-
sures. This tool evaluates the quality and the risk of bias
based on 8 questions. Two independent reviewers (CG
and PK) evaluated all longitudinal studies, and disagree-
ments were resolved by consensus.
Data analysis
An initial analysis of the included leprosy cases was
performed with the aim of creating a clinical and epi-
demiological profile of leprosy after medication-induced
immunosuppression. We searched for factors such as
the type of autoimmune disease, leprosy classification
(paucibacillary (PB) or multibacillary (MB)) geographical
distribution of leprosy cases, leprosy treatment details
and leprosy reaction management in patients.
All longitudinal studies were also separately evaluated.
In this step, we extracted data regarding the new case
detection rate of leprosy (a proxy for incidence and risk
rates when considering immunosuppression as a risk
factor), following the World Health Organization
(WHO) definition [19, 20]. Articles that presented
similarities in quality assessments and methodological
characteristics were selected for the quantitative analysis.
Meta-analysis
For the meta-analysis, we opted to measure the total
period detection rate in selected longitudinal articles to
improve the comparability of the data and to avoid ana-
lytical difficulties due to event rarity. A double arcsine
transformation was applied.
We used the packages “meta”, “metafor” and “weightr”
in the program R Studio for Mac (RStudio, Boston,
USA). RStudio: Integrated Development for R. R Studio,
Inc., Boston, MA, URL http://www.rstudio.com/) to cal-
culate and graphically present the results.
Results
The search resulted in the initial identification of 15,101
articles, and 2 additional references were added while
searching the articles’ references. The application of
automatic and manual duplication exclusion resulted in
the exclusion of 2,851 articles. Title and abstract screen-
ing and subsequent full-text analysis resulted in the
exclusion of 12,061 and 171 articles, respectively. Twenty
articles were finally eligible for data extraction [12, 21–41]
(Fig. 2).
Fig. 1 Current clinical pathway of leprosy in patients under immunosuppression due to rheumatological, dermatological and
gastroenterological diseases
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Thirteen articles were case reports, and three reported
leprosy case series in patients under medication-induced
immunosuppression [24, 32, 37]. Four articles, including
3 observational studies [23, 31, 35] and one clinical trial
[36], evaluated the detection rate of leprosy in immuno-
suppressed patients using longitudinal study designs. In
total, all the included articles reported 24 cases of lep-
rosy in medication-induced immunosuppressed patients.
Clinical profile of leprosy patients
The mean age of leprosy patients who were diag-
nosed after immunosuppression was 48.37 years old
(standard deviation (SD) = 17.01). Most reported
cases were in females (57.89%), and almost all pa-
tients developed leprosy after immunosuppressive
treatment for rheumatological diseases (95.24% of
the reported cases). Thirteen patients had rheuma-
toid arthritis (1 juvenile form), 4 patients had sys-
temic lupus erythematosus (1 juvenile form), 2 had
psoriatic arthritis and 1 had ankylosing spondylitis.
Only one patient had psoriasis [28], and no patient
had gastroenterological disease. In three cases, the
exact reason for medication-induced immunosup-
pression was not disclosed.
Sixteen patients were reported to have been in hy-
perendemic countries at some point in their lives
[42]: 11 had been in Brazil, 3 had been in India and
1 had been in Sri Lanka. One patient had been in
Bolivia, and 1 patient was from China. Interestingly, 1
patient was from Greece [33], and 3 were from the
USA [31, 37]. These 4 patients acquired leprosy in coun-
tries considered nonendemic for leprosy. The patient de-
scribed by Lydakis C et al. in 2012 reported that her father
had been diagnosed with leprosy in Greece 70 years before
and had lived on Spinalonga Island, where persons with
leprosy were confined [33]. Scollard DM et al. 2006 re-
ported two cases of leprosy in the USA. One patient had
never travelled outside the country, and the other patient
reported having had contact with her husband, who hunted
armadillos [37]. In 6 reported cases, the classification of PB
leprosy was described, and in ten patients, the classification
of MB leprosy was described. This information was not
clear in the remaining cases. Treatment followed the WHO
Fig. 2 Flow diagram of article selection
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recommendations for the above-mentioned classifications
(Fig. 3).
The mean duration of autoimmune disease in this
population prior to the diagnosis of leprosy was 11.90
years (SD = 13.94). Thirteen patients were using immuno-
biologics alone or in combination with other immunosup-
pressive drugs (12 used anti-TNF drugs (7 infliximab, 3
etanercept, 1 adalimumab, and 1 not specified) and 1 used
an anti-IL-6 drug (tocilizumab)). Eleven patients reported
a history of steroid use for autoimmune disease control.
Only three patients reported the use of only conventional
immunosuppressive drugs for autoimmune disease
control. Two patients used only methotrexate for the
control of rheumatoid arthritis, and one used a com-
bination of azathioprine, cyclophosphamide and my-
cophenolate mofetil for the control of systemic lupus
erythematosus.
Immunosuppression was not terminated after the diagno-
sis of leprosy was made in only 2 patients [35, 37]. Eleven pa-
tients developed leprosy reactions (9 Type 1 and 2 Type 2
reactions) after the specific diagnosis. In 6 cases, the reinitia-
tion of immunosuppression was necessary to control the lep-
rosy reactions. In two cases, the authors clearly reported that
the treatment of leprosy with the WHO-recommended poly-
chemotherapy did not lead to an adequate response. One of
these patients was treated with the PB treatment scheme (S1
Table 2).
Diagnostic rate evaluation
Four articles with longitudinal designs reported the diag-
nosis rate of leprosy in patients under medication-
induced immunosuppression [23, 31, 35, 36]. In total,
199,611 immunosuppressed patients were evaluated, and
4 cases of leprosy were reported in this population,
resulting in a period diagnostic rate of 2 cases per 100,
000 medication-induced immunosuppressed patients
(pooled detection rate in the total period = 2.00 × 10− 5;
95% CI = 6.42 × 10− 6-5.51 × 10− 5). The detection rate of
leprosy in the 4 included articles ranged from 0.13 lep-
rosy cases per 100,000 patients/year in the USA [31] to
116.18 [23] leprosy cases per 100,000 patients/year in
Brazil. However, different methodologies precluded a
direct comparison among all 4 studies (Table 1).
Quality assessment
Quality assessments were performed for the 4 longitu-
dinal studies (Fig. 4). Only one article was scored as un-
clear for questions related to the inclusion criteria and
the characteristics of the included subjects (Questions 1
and 2, 31]. The outcome measurement, which was the
Fig. 3 Geographical distribution of the included articles and information relevant to the clinical profile of leprosy under medication-induced
immunosuppression. *Map constructed by SV using the program Adobe inDesign (2019, CA, USA)
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diagnosis of leprosy (Question 6), was considered ad-
equate in all articles, as the WHO has established a clear
definition of leprosy. One article was not included in the
meta-analysis because the description of the included
subjects was unclear [31], unlike the other remaining
longitudinal studies that evaluated immunosuppressed
patients suffering from rheumatological diseases.
Meta-analysis
The detection rate was 84 cases of leprosy per 100,000
medication-induced immunosuppressed patients who
were being treated for rheumatic diseases (period detec-
tion rate = 0.00084; 95% CI = 0.0000–0.00266; I2 = 0%,
p = 0.55, 23, 35, 36] (Fig. 5).
Discussion
Leprosy is an endemic disease that reduces the quality
of life in affected patients [40]. The disease affects
underdeveloped regions of the world where important
improvements in the quality of basic health are still
needed [10]. Immunosuppression is considered an import-
ant risk factor for granulomatous infectious diseases [41].
The treatment of autoimmune diseases has undergone
a substantial evolution in recent years. Previously, these
conditions were treated with nonspecific medications,
such as corticosteroids, methotrexate and cyclosporine
[43]. Today, treatment has become personalized, and
newly developed immunobiologics are becoming
available. Regarding leprosy, a main concern is the
targeted use of anti-TNF compounds because they are
Table 1 Epidemiological characteristics of the 4 included articles that presented longitudinal data
















1 312 32 320.50 10.02
Burmester 2016 [36] Rheumatoid Arthritis Tocilizumab 1 1262 2 79.20 39.62
Titton 2011 [23] Rheumatic Diseases; Anti-TNF and DMARDs 1 1037 0.83 96.43 116.18
Wallis RS 2005 [31] Not clear Infliximab 1 197,000 4 0.51 0.13
Total* – – 4 199,611 – 2.00 –
n Number of patients, DMARDs Disease-modifying antirheumatic drugs, * Unadjusted values
Fig. 4 Quality assessment of the longitudinal studies. a The Joanna Briggs Institute (JBI) Checklist for Analytical Cross-Sectional Studies; b
evaluation of longitudinal studies
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responsible for reducing the granulomatous response,
an important factor for the control of mycobacterial
infection [44, 45].
No evidence was found regarding the need to interrupt
immunosuppression after the diagnosis of leprosy, a
common action after the diagnosis of infections in
immunosuppressed patients. Indeed, the reinitiation of
immunosuppressive drugs was necessary in 6 patients to
control reactional states after the introduction of
polychemotherapy.
The leprosy detection rate in the 4 included longitudinal
articles ranged from 0.13 in the USA to 116.18 leprosy
cases per 100,000 patients/year in Brazil. In 2018, only 185
cases of leprosy were reported in the USA (0.06 cases per
100,000) [10]. Our meta-analysis showed a detection rate
of 84 cases of leprosy per 100,000 medication-induced im-
munosuppressed patients suffering from rheumatological
diseases. This detection rate is 30 times higher than the
worldwide detection rate reported in 2018 for the general
population (2.74/100,000) [10] (p < 0.001; 95% CI = 8.85–
88.56). This detection rate was also 6 times higher
than the detection rate reported in endemic countries,
such as Brazil, in 2018 (13.68/100,000, 10] (p < 0.001;
95% CI = 3.41–10.56).
Data analyses point to a higher leprosy detection rate
in patients with medication-induced immunosuppression
suffering from rheumatological diseases than in the gen-
eral population. However, some limitations might be con-
sidered. Initially, the small number of studies precluded
the evaluation of publication bias and the consideration of
confounders in a meta-regression model. It is also import-
ant to state that the variability in case samples was too
low (only one case per study), and considerable variations
attributable to chance may have influenced our results.
Additionally, event rarity may have led to an overesti-
mation of effect sizes [46]. Another limiting factor related
to methodology is the fact that no article regarded leprosy
as a primary outcome, which might have reduced the
reported incidence of leprosy cases.
In the present article, our model showed that the lep-
rosy detection rate was elevated in patients with
medication-induced immunosuppression suffering from
rheumatological diseases. The lack of methodological
rigour and the absence of an active search for leprosy in
the included articles preclude more precise conclusions.
New studies considering the detection of leprosy as a
primary outcome in special populations, including im-
munosuppressed patients, will be needed to answer the
remaining questions. In addition, due to the importance
of the present topic, specialists practicing in endemic
countries must discuss the implementation of an active
leprosy screening strategy before the initiation of immuno-
suppressive treatment for rheumatological diseases.
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